Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial

Jeff P. Sharman, Charles M. Farber, Daruka Mahadevan, Marshall T. Schreeder, Heather D. Brooks, Kathryn S. Kolibaba, Suzanne Fanning, Leonard Klein, Daniel R. Greenwald, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, John M. Burke

Research output: Contribution to journal › Article › peer-review

54 Scopus citations

Fingerprint

Dive into the research topics of 'Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial'. Together they form a unique fingerprint.

Medicine and Dentistry